Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma.
Identifying multiple myeloma patients at highest risk early may help doctors decide to offer CAR T therapy sooner, when it might be most effective.
In this retrospective MSKCC cohort of 208 MM patients receiving CAR T, functionally high-risk disease (progression within 24 months of frontline therapy) was strongly associated with inferior overall survival compared to non-FHR disease. These findings support moving CAR T earlier in the treatment sequence for FHR MM patients.
What the study was
- Study design
- Retrospective single-center cohort study
- Population
- Multiple myeloma patients receiving CAR T-cell therapy at Memorial Sloan Kettering Cancer Center
- Sample size
- 208
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Blood Cancer Journal
Why it surfaced
Large single-center cohort (n=208) directly informs CAR T treatment sequencing in MM; finding that late-line use in FHR disease yields inferior survival supports earlier CAR T deployment, with immediate clinical relevance.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.